# Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

> **NCT00124748** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 476 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic Phase

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00124748
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 476 (ACTUAL)
- **Why stopped:** This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124748, "Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00124748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*